interferon
ifn
ab
critic
effector
innat
immun
respons
viru
infect
activ
ifnab
receptor
ifnar
induc
express
ifnstimul
gene
isg
encod
antivir
protein
capabl
suppress
viral
replic
promot
viral
clearanc
mani
highli
pathogen
virus
evolv
mechan
evad
ifn
respons
balanc
robust
host
immun
respons
viral
antagonist
mechan
determin
whether
viru
clear
discuss
ifn
broadspectrum
antivir
treatment
acut
viru
infect
particular
use
treatment
reemerg
viru
infect
directact
antivir
daa
limit
util
due
daaresist
mutat
newli
emerg
viru
strain
time
vaccin
avail
preclud
vaccin
onset
outbreak
ifnsab
hostderiv
broad
spectrum
antivir
viru
infect
rang
mild
benign
highli
virul
epidem
pandem
significantli
affect
global
health
daa
target
specif
step
viru
replic
vaccin
current
effect
therapeut
intervent
strategi
use
viru
infect
newli
emerg
reemerg
virus
undergon
mutat
may
howev
resist
effect
daa
wherea
vaccin
requir
viru
strain
identifi
vaccin
product
preclud
use
onset
new
viru
infect
outbreak
broadspectrum
antivir
capabl
modul
innat
immun
respons
regardless
infect
viru
present
ideal
candid
firstlin
treatment
acut
viru
infect
respiratori
tract
sexual
transmit
infect
ifnsab
produc
plasmacytoid
dendrit
cell
pdc
macrophag
fibroblast
endotheli
cell
critic
effector
innat
immun
respons
viru
infect
ifnsab
induc
follow
pattern
recognit
receptor
prr
activ
virus
box
review
target
mani
differ
stage
viral
replic
exampl
viral
entri
envelop
uncoat
genom
replic
protein
assembl
releas
viral
progeni
ifnsab
also
activ
differ
cell
type
immun
system
promot
viral
clearanc
induc
apoptosi
cell
prevent
viral
replic
hostderiv
innat
immun
respons
factor
ifn
therefor
broadspectrum
antivir
crucial
primari
host
respons
viral
infect
ifnsab
bind
activ
ifnar
complex
result
rapid
induct
transcript
translat
isg
figur
review
notabl
ifnar
ubiquit
express
cell
lineag
probabl
evolutionari
consequ
differ
virus
abl
target
infect
differ
cell
type
ifnar
express
cell
type
ensur
ifn
respons
viru
may
induc
upon
infect
ifn
respons
central
robust
innat
immun
respons
virus
evolv
varieti
mechan
interfer
ifn
product
signal
disrupt
innat
host
antivir
factor
success
viral
clearanc
determin
balanc
virusencod
molecul
antagon
host
innat
immun
respons
robust
host
innat
immun
respons
discuss
ifn
therapi
present
viabl
treatment
option
rang
acut
viru
infect
target
varieti
tissu
includ
respiratori
tract
infect
sever
acut
respiratori
syndrom
coronaviru
sarscov
influenza
virus
infect
liver
hepat
c
viru
hcv
hepat
b
viru
hbv
mucos
infect
herp
simplex
viru
hsv
may
particularli
import
given
pauciti
broadspectrum
antivir
treat
newli
emerg
reemerg
viru
infect
present
major
threat
human
health
yin
ifn
activ
immun
system
addit
induct
isg
express
cell
type
ifn
shape
landscap
immun
system
respons
viru
infect
promot
neutrophil
surviv
activ
macrophag
natur
killer
cell
dc
b
cell
cell
helper
th
polar
effector
cell
figur
ifn
therapi
therefor
advantag
daa
treatment
addit
stimul
gene
block
viral
replic
infect
cell
ifn
activ
innat
adapt
immun
respons
combat
viru
polymorph
gene
encod
factor
involv
differ
stage
ifn
respons
lead
mark
differ
suscept
viru
infect
sever
diseas
also
serv
predict
marker
outcom
ifn
treatment
exampl
polymorph
host
gene
encod
protein
associ
regul
ifn
respons
interferon
receptor
achain
ifninduc
myxoviru
resist
gtpase
protein
mx
ifninduc
oligoadenyl
synthetas
oa
suppressor
cytokin
signal
soc
associ
regul
ifn
respons
predict
marker
link
rate
sustain
virolog
respons
svr
hcv
infect
follow
ifna
treatment
highlight
import
intact
ifn
respons
viral
infect
indic
genet
variat
among
patient
present
challeng
optim
ifn
therapi
yang
virul
factor
antagon
ifn
respons
surpris
mani
pathogen
virus
includ
sarscov
influenza
virus
hcv
hsv
develop
mechan
disrupt
limit
ifnab
respons
tabl
mani
virus
abl
evad
innat
immun
system
directli
target
pathway
requir
induct
ifnab
product
virus
also
abl
inhibit
ifn
respons
interf
effector
ifninduc
signal
cascad
understand
basi
antagonist
mechan
essenti
optim
time
dosag
ifn
treatment
viabl
therapi
acut
viru
infect
box
ifnab
induct
viral
pathogenassoci
molecular
pattern
pamp
prr
includ
membraneassoci
tolllik
receptor
tlr
cytosol
rna
dna
sensor
rigi
abl
detect
extracellular
endosom
cytosol
viral
pamp
viral
genom
materi
primari
outcom
nonspecif
surveil
system
detect
virus
regardless
target
cell
tissu
tropism
viru
independ
viru
locat
transcript
activ
ifnab
gene
rapid
product
secret
ifn
upon
viral
pamp
recognit
prr
abl
trigger
phosphorylationdepend
signal
cascad
activ
andor
instanc
endosom
rnadnasens
activ
via
myeloid
differenti
primari
respons
gene
wherea
endosom
dsrnabind
rigi
abl
activ
inhibitor
ikk
activ
result
nuclear
transloc
act
transcript
factor
upregul
ifnab
gene
express
ifnsab
bind
high
affin
ifnar
complex
compos
achain
structur
modifi
cell
membran
glycosphingolipid
galabiosylceramid
globotriaosylceramid
promot
effici
ifn
bind
bchain
ifn
bind
ifnar
induc
phosphoryl
receptorbound
tyrosin
kinas
tyrosin
kinas
lead
subsequ
regul
protein
synthesi
via
activ
mammalian
target
rapamycin
mtor
b
histon
modif
via
activ
mapk
c
gene
express
via
phosphoryl
stat
protein
mapk
activ
activ
insulin
receptor
substrat
ir
requir
recruit
activ
phosphoryl
akt
inactiv
inhibitor
mtor
tuber
sclerosi
protein
tsc
mtor
activ
serin
threonin
kinas
inactiv
eukaryot
translat
initi
factor
protein
upregul
capdepend
mrna
translat
protein
synthesi
activ
downstream
mapk
kinas
regul
histon
modif
gene
express
mitogenand
stressactiv
protein
kinas
msk
addit
ifn
signal
invok
promyelocyt
leukemia
zinc
finger
plzf
proteinmedi
histon
modif
regul
isg
express
phosphoryl
stat
protein
result
dimer
ifnstimul
gene
factor
isgf
format
stat
complex
transloc
nucleu
bind
specif
gene
element
promot
isg
ifng
activ
sequenc
ga
ifnsensit
respons
element
isr
induc
express
antivir
gene
ifn
therapi
firstlin
treatment
newli
emerg
reemerg
viru
outbreak
sarscov
sarscov
outbreak
origin
hong
kong
late
result
case
diseas
worldwid
mortal
rate
novemb
juli
http
wwwwhointcsrsarscountri
sarscov
singlestrand
rna
viru
encod
genom
virul
factor
antagon
ifnab
respons
infect
host
cell
sarscov
express
nonstructur
protein
nsp
suppress
host
gene
express
disrupt
mrna
translat
upregul
mrna
degrad
immunoprecipit
luciferas
report
studi
shown
directli
associ
ribosom
subunit
inhibit
translat
activ
addit
complex
abl
modifi
matur
cap
rna
limit
translat
promot
degrad
context
ifn
respons
antagonist
mechan
host
gene
express
protein
synthesi
inhibit
ifnab
express
product
vitro
also
inhibit
signal
transduc
activ
transcript
stat
protein
phosphoryl
induc
ifna
treatment
inhibit
interferon
regulatori
factor
irf
activ
downregul
ifn
product
respons
viral
infect
specif
inhibit
human
bronchial
epitheli
cell
via
papainlik
proteas
plp
domain
tripartit
motifcontain
protein
antivir
factor
limit
infect
transcript
factor
jund
jund
claudin
ifn
treatment
prime
cell
apoptosi
modul
express
proteasom
subunit
major
histocompat
complex
mhc
class
fa
receptor
ifnsab
also
contribut
activ
differenti
cell
involv
b
innat
c
adapt
immun
respons
viru
infect
ifnab
induc
product
interleukin
il
dc
macrophag
modul
b
cell
differenti
polar
activ
ifnb
signal
pdc
lead
alter
receptor
express
therebi
affect
pdc
retent
lymph
node
ifnsab
increas
mhc
class
ii
express
antigen
present
cell
ifnab
treatment
induc
macrophag
neutrophil
phagocytosi
moreov
ifnsab
promot
neutrophil
surviv
activ
cellular
inhibitor
apoptosi
natur
killer
nk
cell
respond
ifnsab
increas
fa
ligand
fasl
perforin
express
ifng
product
respons
ifnsab
b
cell
upregul
lselectin
igg
product
trend
immunolog
april
vol
interact
inhibit
phosphoryl
nuclear
transloc
addit
open
read
frame
matrix
protein
sarscov
also
inhibit
ifn
respons
local
host
endoplasm
reticulum
er
block
transcript
factor
function
phosphoryl
bind
nuclear
import
factor
prevent
transloc
nucleu
protein
interact
rna
sensor
retino
acidinduc
gene
rigi
rna
helicas
key
intracellular
prr
associ
induct
irfdepend
ifn
product
follow
detect
viral
rna
protein
also
interact
signal
effector
serinethreonineprotein
kinas
inhibitor
nuclear
factorkb
kinas
subunit
e
ikk
tumor
necrosi
factor
tnf
associ
factor
associ
ifn
gene
induct
thu
multipl
mechan
sarscov
might
inhibit
host
ifn
respons
implic
ifn
respons
sarscov
infect
must
dramat
limit
viru
replic
proceed
suggest
domin
immun
respons
ifn
respons
differ
recombin
ifna
ifnb
approv
variou
clinic
indic
includ
treatment
chronic
hcv
infect
comprehens
analysi
structur
featur
ifnab
moleculescruci
cluster
amino
acidsaffect
sensit
target
cell
ifninduc
biolog
respons
specif
epitop
expos
surfac
ifn
molecul
identifi
associ
receptor
recognit
accumul
evid
suggest
affin
particular
ifnab
subtyp
ifnar
determin
biopot
ifn
specif
context
antivir
antiprolif
respons
direct
consequ
design
develop
synthet
ifna
ifn
exhibit
optim
affin
ifnar
initi
treatment
sarscov
infect
focus
use
daa
ribavirin
combin
corticosteroid
therapi
howev
pilot
clinic
studi
therapeut
potenti
ifn
evalu
individu
infect
sarscov
hospit
toronto
canada
ifn
treatment
togeth
corticosteroid
associ
reduc
diseaseassoci
impair
oxygen
satur
rapid
resolut
radiograph
lung
abnorm
lower
level
diseaseassoci
creatin
kinas
vitro
studi
examin
mechan
action
ifn
sarscov
reveal
ifninduc
janu
kinas
protein
kinas
c
pkc
mitogenactiv
protein
kinas
mapk
activ
mediat
ifn
antivir
protect
target
gene
downstream
activ
kinas
differenti
express
peripher
blood
cell
sar
patient
treat
ifn
compar
patient
treat
ifn
function
gene
associ
antimicrobi
activ
treatment
human
bronchial
epitheli
cell
line
ifn
infect
sarscov
result
inhibit
viru
infect
reduct
overal
viru
yield
support
idea
ifn
demonstr
antivir
activ
sarscov
data
demonstr
despit
inher
abil
sarscov
inhibit
ifn
product
limit
ifn
respons
treatment
exogen
ifna
overrid
inhibitori
effect
result
support
evalu
ifn
firstlin
treatment
acut
sarscov
infect
approv
inhibit
function
pkr
oa
via
dsrnabind
domain
review
trend
immunolog
april
vol
random
clinic
trial
protocol
place
usa
canada
outbreak
sarscov
season
influenza
viru
infect
consider
health
burden
vaccin
program
current
implement
develop
countri
vaccin
howev
relev
outbreak
involv
emerg
variant
swineorigin
influenza
viru
prime
exampl
quickli
pandem
develop
given
potenti
genet
shift
mutat
influenza
virus
among
natur
host
pandem
daa
neuraminidas
inhibitor
oseltamivir
zanamivir
wide
use
vaccin
becam
avail
surprisingli
howev
daaresist
variant
pandem
emerg
avian
influenza
viru
outbreak
affect
popul
throughout
asia
europ
associ
mortal
rate
around
notabl
number
strain
resist
oseltamivir
date
report
case
humantohuman
transmiss
lethal
influenza
viru
infect
newli
emerg
strain
capabl
humantohuman
transmiss
appear
daa
resist
develop
vaccin
becom
availableprob
monthspopul
risk
absenc
access
broadspectrum
antivir
primari
virul
factor
encod
influenza
virus
express
host
cell
earliest
stage
infect
comparison
sarscov
influenza
viru
overlap
function
well
uniqu
mechan
inhibit
ifn
respons
act
nucleu
cytoplasm
infect
cell
primari
antagonist
host
innat
immun
respons
remark
evolv
inhibit
virtual
stage
ifn
respons
viru
infect
includ
inhibit
ifn
product
interfer
ifn
signal
event
inhibit
function
antivir
factor
induc
ifn
signal
inhibit
activ
rigi
box
dsrnabind
domain
interact
directli
rigi
within
nucleu
infect
cell
inhibit
process
synthesi
host
mrna
includ
ifnab
mrna
bind
inhibit
cleavag
polyadenyl
specif
factor
kda
poli
bind
protein
ii
pabpii
via
proteinbind
domain
express
avian
disrupt
ifn
signal
event
downregul
surfac
express
one
ifnar
subunit
upregul
protein
express
lead
reduct
ifninduc
stat
phosphoryl
stat
homoheterodim
nuclear
transloc
abl
block
directli
antivir
activ
ifninduc
antivir
protein
protein
kinas
rnaactiv
pkr
oasrnasel
via
proteinbind
domain
dsrnabind
domain
respect
src
homolog
bind
domain
within
proteinbind
region
permit
interact
intern
domain
inhibitori
subunit
phosphoinositid
lead
activ
pathway
activ
downstream
target
ifnab
signal
specif
promot
cell
surviv
earli
stage
infect
illustr
complex
interplay
viru
encod
factor
ifnab
respons
remark
distinct
highli
pathogen
respiratori
virus
name
influenza
virus
sarscov
encod
nonstructur
protein
genom
function
virul
factor
specif
target
host
innat
ifn
respons
emphas
import
ifn
broadspectrum
antivir
recent
complet
random
control
trial
examin
safeti
efficaci
recombin
ifna
rifna
treatment
administ
form
nasal
spray
militari
recruit
context
protect
respiratori
viru
infect
serum
igm
level
measur
evid
viru
infect
subject
receiv
rifna
lower
concentr
serum
igm
specif
influenza
viru
influenza
b
viru
adenoviru
speci
b
parainfluenza
viru
type
specif
regard
influenza
viru
recruit
treat
rifna
detect
level
influenza
viru
igm
compar
recruit
untreat
control
group
advers
event
report
treatment
group
data
demonstr
ifn
well
toler
effect
prevent
varieti
common
viral
respiratori
infect
thu
sarscov
implic
treatment
ifna
overrid
inhibitori
effect
ifn
respons
influenza
viru
infect
ifn
therapi
highli
pathogen
oncogen
viral
infect
hbv
hcv
worldwid
million
peopl
infect
hcv
result
approxim
death
year
http
estim
million
peopl
chronic
infect
hbv
result
approxim
death
year
http
hcv
hbv
target
liver
caus
acut
chronic
infect
result
liver
cirrhosi
eventu
hepatocellular
carcinoma
current
approv
standardofcar
treatment
hcv
infect
compris
daili
ribavirin
combin
weekli
pegyl
ifna
pegifna
coval
linkag
polyethylen
glycol
ifna
increas
halflif
ifna
circul
common
side
effect
associ
ifn
therapi
includ
rang
flulik
symptom
fatigu
fever
myalgia
often
diminish
spontan
first
week
therapi
sever
neuropsychiatr
disturb
includ
sleep
disturb
depress
mood
chang
onset
within
first
month
ifn
therapi
hematolog
disturb
neutropenia
anemia
may
occur
respons
ifn
dose
reduct
treatment
granulocyt
colonystimul
factor
gcsf
erythropoietin
epo
respect
combin
ifnribavirin
therapi
success
patient
infect
hcv
genotyp
patient
go
achiev
svr
character
undetect
hcv
rna
follow
week
treatment
rate
svr
fall
patient
infect
hcv
genotyp
trend
immunolog
april
vol
follow
week
treatment
pegifna
ribavirin
incomplet
respons
ifn
treatment
partial
attribut
viral
encod
virul
factor
interfer
ifn
respons
hcv
serin
proteas
target
mitochondri
antivir
signal
mav
protein
requir
rigimedi
activ
subsequ
ifn
product
recent
secondari
structur
hcv
genotyp
ntermin
region
identifi
predict
marker
virolog
respons
patient
receiv
ifn
ribavirin
combin
therapi
week
specif
polymorph
secondari
structur
aminotermin
region
segreg
hcv
genotyp
infect
individu
two
group
predict
virolog
respons
pegifn
plu
ribavirin
therapi
associ
intracellular
membran
express
vital
hcv
genom
replic
abl
interact
ifninduc
pkr
evad
ifninduc
antivir
respons
polymorph
amino
acid
residu
hcv
core
also
predict
marker
virolog
respons
patient
receiv
ifn
ribavirin
therapi
notabl
target
ifn
ifnactiv
gene
interferon
stimul
gene
encod
protein
promot
isgyl
enhanc
degrad
therebi
inhibit
hcv
replic
addit
hcv
hcv
envelop
protein
intern
ribosom
entri
site
ire
abl
inhibit
ifninduc
pkr
activ
contain
eukaryot
translat
initi
factor
phosphoryl
homolog
domain
abl
interact
pkr
wherea
hcv
ire
bind
pkr
preclud
dsrna
bind
therebi
prevent
pkr
activ
despit
potent
inhibitori
effect
hcvencod
factor
ifn
respons
clinic
data
provid
direct
evid
pegifna
treatment
combin
ribavirin
effect
limit
hcv
infect
depend
hcv
genotyp
may
invok
svr
mechan
hbv
evad
innat
immun
respons
less
well
understood
hbv
polymeras
pol
block
irf
signal
subsequ
ifn
product
inhibit
activ
associ
prr
signal
inhibit
mediat
direct
proteinprotein
interact
pol
host
dead
box
dead
amino
acid
sequenc
motif
rna
helicas
enhanc
activ
pegifna
effect
treatment
hbv
infect
suggest
ifn
treatment
overcom
virusimpos
inhibit
innat
immun
respons
specif
ifn
product
pegifna
effect
treatment
option
hepat
b
e
core
antigen
hbeag
posit
diseas
detect
hbeag
blood
indic
viral
replic
hbeagposit
patient
treat
pegifna
abl
develop
hbeagspecif
antibodi
seroconvers
month
end
treatment
percentag
rise
year
end
treatment
comparison
monotherapi
daa
lamivudin
lead
emerg
mutant
lamivudineresist
hbv
strain
pegifna
alon
combin
lamivudin
effect
induc
hbeag
seroconvers
although
side
effect
report
patient
receiv
pegifna
contrast
hbeagposit
diseas
pegifna
alon
combin
ribavirin
limit
effect
patient
late
stage
hbeagneg
diseas
hbv
mutat
result
loss
hbeag
express
random
clinic
trial
percentag
hbeagneg
patient
hbv
dna
level
copiesml
receiv
pegifna
monotherapi
drop
end
treatment
week
later
stage
viral
diseas
therefor
affect
efficaci
ifn
therapi
time
treatment
contribut
capac
resolv
infect
moreov
influenza
virus
sarscov
despit
hbv
hcv
encod
viral
factor
antagon
ifn
respons
exogen
ifn
therapi
proven
effect
treatment
establish
svr
ifn
therapi
highli
transmiss
viral
infect
highli
contagi
viru
preval
among
sexual
transmit
infect
abl
establish
latent
infect
immunocompet
individu
evad
immun
system
reactiv
host
immun
system
weaken
genom
encod
number
virul
factor
name
infect
cell
protein
icp
associ
immunoevas
suppress
innat
immun
respons
viru
infect
specif
dephosphoryl
revers
pkrmediat
inactiv
local
cytoplasm
inhibit
activ
blunt
ifninduc
jakstat
signal
pathway
inhibit
ifninduc
phosphoryl
nuclear
transloc
furthermor
hsv
structur
protein
dsrnabind
domain
disrupt
activ
ifninduc
antivir
protein
oa
pkr
immunocompromis
individu
infect
viral
pathogenesi
lead
seriou
lifethreaten
diseas
context
emerg
drugresist
strain
differ
daa
use
control
infect
includ
acyclovir
penciclovir
foscarnet
result
emerg
daaresist
strain
ifng
abl
exert
antivir
activ
stimul
cell
respons
howev
ifng
alon
may
limit
efficaci
immunocompromis
individu
lack
robust
adapt
immun
respons
recent
studi
shown
immunocompromis
nude
mice
infect
daa
acyclovir
resist
variant
treat
ifnb
combin
ifng
viral
infect
reduc
preliminari
data
support
broadspectrum
antivir
activ
ifnsab
shift
balanc
favor
host
innat
immun
respons
futur
ifn
antivir
therapi
mechan
viral
evas
host
immun
respons
includ
express
mani
virul
factor
review
trend
immunolog
april
vol
singl
viru
target
differ
stage
ifn
respons
express
singl
highli
special
molecul
alon
target
multipl
facet
ifn
respons
priori
widespread
exist
viral
encod
virul
factor
target
ifn
respons
highlight
critic
role
robust
ifn
respons
limit
viru
infect
abil
ifnsab
target
multipl
type
virus
differ
stage
viral
replic
ubiquit
express
ifn
receptor
cell
suscept
differ
viru
infect
differ
tissu
tropism
well
abil
ifn
activ
innat
immun
cell
influenc
adapt
immun
respons
emphas
relev
ifnsab
broadspectrum
antivir
understand
viral
strategi
evas
ifn
permit
design
strateg
ifn
treatment
regimen
protect
clear
viru
infect
opportun
limit
viru
infect
even
absenc
character
specif
infect
viru
realiti
outbreak
unknown
etiolog
pandem
newli
emerg
reemerg
viru
strain
profound
implic
global
health
inde
earli
data
indic
ifn
therapi
may
effect
treat
west
nile
viru
hemorrhag
yellow
fever
viru
ebola
viru
infect
moreov
shortterm
ifn
therapi
acut
viru
infect
may
invok
debilit
side
effect
associ
longterm
ifn
therapi
chronic
infect
hbv
hcv
preliminari
data
pilot
clinic
trial
ifn
treatment
sarscov
influenza
virus
show
case
cogniz
yin
yang
virus
ifn
open
door
widespread
clinic
applic
broadspectrum
antivir
ifn
